Can radiomics help to predict skeletal muscle response to chemotherapy in stage IV non-small cell lung cancer?

•This was the first attempt to evaluate the potential of muscle radiomics to predict muscle loss.•Fifty-nine percent of patients with non-small cell lung cancer exhibited loss of skeletal muscle during chemotherapy.•Skeletal muscle radiomics did not predict future muscle loss.